RT 100

Drug Profile

RT 100

Alternative Names: Ad5.hAC6; Adenylate cyclase gene therapy - Renova; RT100

Latest Information Update: 03 Nov 2016

Price : $50

At a glance

  • Originator Renova Therapeutics
  • Class Gene therapies
  • Mechanism of Action Adenylate cyclase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Heart failure

Most Recent Events

  • 01 Nov 2016 Renova Therapeutics plans a phase III trial for Heart failure in USA
  • 30 Mar 2016 Efficacy data from a phase I/II trial in Heart failure released by Renova Therapeutics
  • 14 Jan 2016 Renova Therapeutics completes phase II of phase I/II trial in Heart failure in USA (NCT00787059)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top